SELLAS Life Sciences
25 hedge funds and large institutions have $4.91M invested in SELLAS Life Sciences in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 4 closing their positions.
6,973% more call options, than puts
Call options by funds: $3.18M | Put options by funds: $45K
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
15% more capital invested
Capital invested by funds: $4.28M → $4.91M (+$624K)
14% more funds holding
Funds holding: 22 → 25 (+3)
0.44% more ownership
Funds ownership: 10.59% → 11.03% (+0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$80K |
| 2 |
PFG
Prosperity Financial Group
San Ramon,
California
|
+$47.9K |
| 3 |
BlackRock
New York
|
+$35.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.8K |
| 5 |
IFG
Independent Financial Group
San Diego,
California
|
+$20.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$44.8K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.46K |
| 4 |
Bank of New York Mellon
New York
|
-$143 |
| 5 |
VFA
Values First Advisors
Gray,
Tennessee
|
-$21 |
SLS Hedge Fund Activity: Q2 2023 in Review
25 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2023, worth a combined $4.91M — up 15% from $4.28M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SLS positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $80K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $44.8K sold.
- 25 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2023, up from 22 in Q1 2023.
- Funds reported $4.91M of SELLAS Life Sciences stock for Q2 2023, up 15% quarter-over-quarter.
- 7 funds opened new SELLAS Life Sciences positions in Q2 2023 and 4 closed out, a net change of +3 holders.
- The largest SELLAS Life Sciences buyer in Q2 2023 was Vanguard Group, an estimated $80K added.
- The largest SELLAS Life Sciences seller in Q2 2023 was Dimensional Fund Advisors, an estimated $44.8K sold.
Based on aggregated 13F filings for Q2 2023.